+Compare
PTN
Stock ticker:
ASE
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
28.12M

PTN Palatin Technologies Forecast, Technical & Fundamental Analysis

a developer of peptide, peptide mimetic and small molecule agonist compounds

Industry Biotechnology
GET INTRADAY SIGNALS
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT May 26, 2023

PTN's Indicator enters downward trend

The Aroon Indicator for PTN entered a downward trend on May 03, 2023. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 310 similar instances where the Aroon Indicator formed such a pattern. In of the 310 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 47 cases where PTN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PTN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PTN broke above its upper Bollinger Band on May 15, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PTN's RSI Indicator exited the oversold zone, of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on May 15, 2023. You may want to consider a long position or call options on PTN as a result. In of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PTN just turned positive on May 11, 2023. Looking at past instances where PTN's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PTN advanced for three days, in of 249 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.931) is normal, around the industry mean (24.787). P/E Ratio (0.000) is within average values for comparable stocks, (122.999). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.316). Dividend Yield (0.000) settles around the average of (0.030) among similar stocks. P/S Ratio (6.540) is also within normal values, averaging (303.223).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. PTN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PTN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.11B. The market cap for tickers in the group ranges from 365 to 363.13B. NONOF holds the highest valuation in this group at 363.13B. The lowest valued company is CLAZF at 365.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -1%. For the same Industry, the average monthly price growth was 49%, and the average quarterly price growth was 53%. LABP experienced the highest price growth at 871%, while RAIN experienced the biggest fall at -89%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 22%. For the same stocks of the Industry, the average monthly volume growth was 18% and the average quarterly volume growth was 28%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 86
Price Growth Rating: 55
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: 18 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

PTN is expected to report earnings to fall 26.98% to -46 cents per share on September 26

Palatin Technologies PTN Stock Earnings Reports
Q2'23
Est.
$-0.46
Q1'23
Missed
by $0.27
Q4'22
Beat
by $0.45
Q3'22
Missed
by $0.28
Q2'22
Missed
by $0.53
The last earnings report on May 16 showed earnings per share of -62 cents, missing the estimate of -36 cents. With 27.48K shares outstanding, the current market capitalization sits at 28.12M.
A.I. Advisor
published General Information

General Information

a developer of peptide, peptide mimetic and small molecule agonist compounds

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
4B Cedar Brook Drive
Phone
+1 609 495-2200
Employees
33
Web
https://www.palatin.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
XMTR18.721.58
+9.22%
Xometry
YI2.540.04
+1.60%
111, Inc
PALT2.850.03
+1.06%
Paltalk
HP32.74-0.07
-0.21%
Helmerich & Payne
GOLD16.99-0.10
-0.59%
Barrick Gold Corp

PTN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTN has been loosely correlated with FATE. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if PTN jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTN
1D Price
Change %
PTN100%
+3.83%
FATE - PTN
41%
Loosely correlated
+1.79%
CVAC - PTN
33%
Loosely correlated
-2.97%
MOR - PTN
33%
Loosely correlated
-2.02%
MDGL - PTN
32%
Poorly correlated
+1.17%
MNOV - PTN
32%
Poorly correlated
+1.42%
More

Groups containing PTN

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTN
1D Price
Change %
PTN100%
+3.83%
peptide
(undefined stocks)
31%
Poorly correlated
+1.52%
biotechnology
(undefined stocks)
30%
Poorly correlated
+0.76%
drugs
(undefined stocks)
29%
Poorly correlated
+0.97%
small molecule
(undefined stocks)
11%
Poorly correlated
-1.31%